OSTEOARTHRITIS
Comparing efficacy and safety of Hylan G-F 20 and LMW hyaluronic acid for knee OA
BioDrugs. 2016 Oct;30(5):387-396Twenty randomized controlled trials (RCTs) were included in a meta-analysis and systematic review comparing pain, treatment-emergent adverse events, and function between Hylan G-F 20 injections and low-molecular-weight hyaluronic acid (LMWHA) injections for knee osteoarthritis. No significant differences between products were observed in pain overall or the incidence of treatment-emergent related adverse events. When subgrouped based on follow-up time, significantly lower pain scores were observed favouring Hylan G-F 20 from 5-12 weeks, though no significant differences were observed at other follow-up time periods.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
